By: Elizabeth Gregerson

Deep learning AI models can analyze molecular and prognostic information found through routine pathology to predict tumor recurrence among patients with meningiomas, according to a study published June 5 in The Lancet Digital Health

The models provide the same tumor information as genetic profiling, cutting down the need for the often costly and time-consuming tests, researchers from Rochester, Minn.-based Mayo Clinic said in a June 8 news release.

“Drawing on multiple de-identified datasets, the models were able to classify meningioma subtypes and predict recurrence risk using standard pathology slides that are already part of routine patient care,” the release said. 

Read the full study here. 

At the Becker’s Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.

Next Up in Oncology

  • Stamford (Conn.) Health will build a new cancer center and behavioral health facility as part of a $275 million expansion…

  • Radiation oncologists at Stanford (Calif.) Medicine have treated the first patient using its upright, compact proton therapy delivery system at…

  • As researchers continue studying GLP-1 drugs like Ozempic and Mounjaro in a range of conditions beyond their approved uses, a…

Join the Oncology leaders who start their day with Becker’s